Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (421-430 of 471) with videos related to

Pageof 48
Sort By:
JACC. Heart Failure|November 21, 2024
Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum: The PARAGON-HF TrialFinnian R Mc Causland, Muthiah Vaduganathan, Brian Claggett, et al.
European Journal of Heart Failure|January 6, 2022
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failureFinnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, et al.
European Journal of Heart Failure|March 2, 2006
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunctionLars Køber, Karl Swedberg, John J V McMurray, et al.
European Heart Journal|March 1, 2008
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT studyEldrin F Lewis, Eric J Velazquez, Scott D Solomon, et al.
The New England Journal of Medicine|November 12, 2003
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothMarc A Pfeffer, John J V McMurray, Eric J Velazquez, et al.
Journal of the American Heart Association|April 23, 2025
Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM-HFMisato Chimura, Jawad H Butt, Shingo Matsumoto, et al.
Circulation. Heart Failure|November 17, 2017
Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic CardiomyopathyLi Shen, Felix Ramires, Felipe Martinez, et al.
European Journal of Heart Failure|December 19, 2019
Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fractionKieran F Docherty, Li Shen, Davide Castagno, et al.
European Journal of Heart Failure|November 20, 2024
Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HFSharmistha Datta Gupta, Jawad H Butt, Eoghan G M McMurray, et al.
European Journal of Heart Failure|December 2, 2017
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HFUlrik M Mogensen, Lars Køber, Pardeep S Jhund, et al.
Pageof 48

Showing results (421-430 of 471) with videos related to

Sort By:
Pageof 48
JACC. Heart Failure|November 21, 2024
Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum: The PARAGON-HF TrialFinnian R Mc Causland, Muthiah Vaduganathan, Brian Claggett, et al.
European Journal of Heart Failure|January 6, 2022
Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failureFinnian R Mc Causland, Martin P Lefkowitz, Brian Claggett, et al.
European Journal of Heart Failure|March 2, 2006
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunctionLars Køber, Karl Swedberg, John J V McMurray, et al.
European Heart Journal|March 1, 2008
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT studyEldrin F Lewis, Eric J Velazquez, Scott D Solomon, et al.
The New England Journal of Medicine|November 12, 2003
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothMarc A Pfeffer, John J V McMurray, Eric J Velazquez, et al.
Journal of the American Heart Association|April 23, 2025
Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM-HFMisato Chimura, Jawad H Butt, Shingo Matsumoto, et al.
Circulation. Heart Failure|November 17, 2017
Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic CardiomyopathyLi Shen, Felix Ramires, Felipe Martinez, et al.
European Journal of Heart Failure|December 19, 2019
Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fractionKieran F Docherty, Li Shen, Davide Castagno, et al.
European Journal of Heart Failure|November 20, 2024
Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HFSharmistha Datta Gupta, Jawad H Butt, Eoghan G M McMurray, et al.
European Journal of Heart Failure|December 2, 2017
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HFUlrik M Mogensen, Lars Køber, Pardeep S Jhund, et al.
Pageof 48